1. Home
  2. STOK vs DEI Comparison

STOK vs DEI Comparison

Compare STOK & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$27.86

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$10.83

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
STOK
DEI
Founded
2014
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2019
2006

Fundamental Metrics

Financial Performance
Metric
STOK
DEI
Price
$27.86
$10.83
Analyst Decision
Strong Buy
Hold
Analyst Count
10
8
Target Price
$34.50
$14.79
AVG Volume (30 Days)
812.5K
2.5M
Earning Date
11-04-2025
02-10-2026
Dividend Yield
N/A
6.83%
EPS Growth
N/A
N/A
EPS
0.68
0.12
Revenue
$205,632,000.00
$1,000,336,000.00
Revenue This Year
$430.24
$2.92
Revenue Next Year
N/A
$1.57
P/E Ratio
$41.92
$89.29
Revenue Growth
1128.17
3.61
52 Week Low
$5.35
$10.79
52 Week High
$38.69
$18.61

Technical Indicators

Market Signals
Indicator
STOK
DEI
Relative Strength Index (RSI) 40.11 36.72
Support Level $25.21 $10.80
Resistance Level $31.70 $11.18
Average True Range (ATR) 2.09 0.29
MACD -0.58 0.02
Stochastic Oscillator 27.86 9.81

Price Performance

Historical Comparison
STOK
DEI

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.

Share on Social Networks: